Replies to post #1204 on RedHill Biopharma Ltd (RDHL)

[toddski]

Yes sir it is.

On another note, the Crohn's Disease drug GED-0301 that Celgene acquired from Mongerson for $710M!!! has it's trial discontinued. All I can say is HOLY COW, 700M for a drug that didn't even pass the interim efficacy, so bad in fact that they are discontinuing it. Can you say write off? On the flip side, in 2018 Redhill will have the best performing crohn's treatment data ever released, imo. Expect a deal similar if not bigger than GED-0301 for a drug that actually works, lmao. See below.

http://ir.celgene.com/releasedetail.cfm?ReleaseID=1044647